TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9246960

Group type: EXPERIMENTAL
Intervention: Single-dose of 1.2 g Augmentin at induction of anesthesia
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 8042122

Group type: EXPERIMENTAL
Intervention: Face-to-face interventions focused on individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-level interventions focused on vulnerable communities
Number of subjects: 0
Study: 2500137

Group type: EXPERIMENTAL
Intervention: i.v. immune globulin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31846857

Group type: EXPERIMENTAL
Intervention: RANAS-based intervention
Number of subjects: 224

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 224
Study: 31515567

Group type: EXPERIMENTAL
Intervention: Game-based chin tuck against resistance exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Head-lift exercise
Number of subjects: 37
Study: 28854884

Group type: EXPERIMENTAL
Intervention: Optimization program of drug prescribing consisting of a clinical medication review by a pharmacist, in collaboration with specialist physician of the geriatric/memory center and the referent physician.
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 302
Study: 25277272

Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation therapy (ADT) with docetaxel
Number of subjects: 385

Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (ADT) without docetaxel
Number of subjects: 385
Study: 24100934

Group type: EXPERIMENTAL
Intervention: Financial incentives of £15 (€17; $22) for each depot injection over a 12 month period
Number of subjects: 141

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 141
Study: 21734640

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Mycophenolate/dexamethasone
Number of subjects: 192
Study: 19396507

Group type: EXPERIMENTAL
Intervention: Manual in-line stabilization (MILS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (optimal head position)
Number of subjects: 200
Study: 16794160

Group type: COMPARATOR
Intervention: Metal cannula without anesthetic
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Metal cannula with paracervical anesthetic block
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Flexible balloon catheter
Number of subjects: 89
Study: 12492745

Group type: EXPERIMENTAL
Intervention: Pantoprazole 10 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 371

Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 371
Study: 11071030

Group type: EXPERIMENTAL
Intervention: Patients with posterior capsule rupture with or without vitreous loss (PCR +/‐ VL), n=192
Number of subjects: 2794

Group type: COMPARATOR
Intervention: Patients with no complications, n=275
Number of subjects: 2794
Study: 9288408

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7906190

Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg oral daily
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lamotrigine and Placebo
Number of subjects: 67
Study: 3307890

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine plus cimetidine 400 mg q.d.s. (21 patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chlorpheniramine plus placebo (19 patients)
Number of subjects: 120
Study: 31950895

Group type: EXPERIMENTAL
Intervention: Dynamic Neuromuscular Stabilization (DNS) training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Physical fitness (PF) training
Number of subjects: 34
Study: 30497638

Group type: EXPERIMENTAL
Intervention: Food served in FCCHs
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Food consumed by children
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Food served
Number of subjects: 166
Study: 28692641

Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate (oral) for 7 days
Number of subjects: 187

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 187
Study: 25602580

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 23430708

Group type: EXPERIMENTAL
Intervention: Individual counseling plus nicotine replacement treatment (NRT)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Computer-based Internet smoking treatment plus NRT
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Self-help plus NRT
Number of subjects: 209
Study: 21958958

Group type: EXPERIMENTAL
Intervention: Paracetamol (12 mg/kg single dose)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt (40 mg, open-label)
Number of subjects: 97
Study: 18436083

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (adjusted for proteinuria)
Number of subjects: 842

Group type: COMPARATOR
Intervention: Randomized treatment group (blood pressure goal or antihypertensive drug)
Number of subjects: 842
Study: 16611714

Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced computerized tomography (CT) scan
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Heavy aspirin ingestion
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Total analgesic ingestion > or =0.3 kg/yr
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced CT scan
Number of subjects: 221
Study: 12893983

Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine daily for 54 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine vs. placebo in CC genotype carriers
Number of subjects: 111
Study: 11113039

Group type: EXPERIMENTAL
Intervention: (192)Ir
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8871138

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg, n = 71)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Acetaminophen (n = 73)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo (n = 75)
Number of subjects: 219
Study: 1735852

Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study: 6131624

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg orally
Number of subjects: 100

Group type: COMPARATOR
Intervention: Magnesium trisilicate (control group)
Number of subjects: 100
Study: 31353364

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T‐VEC) plus ipilimumab
Number of subjects: 198

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 198
Study: 29467053

Group type: EXPERIMENTAL
Intervention: Transfer with nutrition behaviour change communication (BCC)
Number of subjects: 4840
Study: 27351678

Group type: EXPERIMENTAL
Intervention: Methylene blue
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24135389

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 371

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 371

Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Metformin + Rosiglitazone
Number of subjects: 371
Study: 21227460

Group type: EXPERIMENTAL
Intervention: L-D (use of laparoscopic instruments with direct vision)
Number of subjects: 36

Group type: COMPARATOR
Intervention: C-V (use of conventional instruments with indirect vision via a video monitor)
Number of subjects: 36

Group type: COMPARATOR
Intervention: L-V (standard laparoscopic suturing and knot tying)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HUESAD assessment
Number of subjects: 36
Study: 20117252

Group type: EXPERIMENTAL
Intervention: Oral furosemide (40mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Furosemide + oral volume replacement (F+R)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Furosemide and F+R
Number of subjects: 14
Study: 17295570

Group type: EXPERIMENTAL
Intervention: Interpretive group therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 110
Study: 15780739

Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) of recombinant hepatitis B vaccine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard dose (20 microg) of recombinant hepatitis B vaccine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with CD4 cell counts > or = 350 cells/mm3
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with CD4 cell counts > or = 350 cells/mm3
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with CD4 cell counts < 350 cells/mm3
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with CD4 cell counts < 350 cells/mm3
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with HIV viral load < 10,000 copies/mL
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with HIV viral load < 10,000 copies/mL
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Double dose (40 microg) for patients with HIV viral load > or = 10,000 copies/mL
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard dose (20 microg) for patients with HIV viral load > or = 10,000 copies/mL
Number of subjects: 210
Study: 11919486

Group type: EXPERIMENTAL
Intervention: NVP plus zidovudine (twice daily for 1 week)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Single dose NVP alone
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control (untreated infants born to HIV-uninfected women)
Number of subjects: 800
Study: 10413343

Group type: EXPERIMENTAL
Intervention: Dynamic stimuli generated by alternating rotations in the horizontal plane of the seat of the chair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study: 7785480

Group type: EXPERIMENTAL
Intervention: Episodic drinking
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Sporadic drinking
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Steady drinking
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Binge drinking
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pretreatment drinking pattern
Number of subjects: 94
Study: 2078960

Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 78

Group type: COMPARATOR
Intervention: BSS
Number of subjects: 78
Study: 7438350

Group type: EXPERIMENTAL
Intervention: Postpericardiotomy syndrome (PPS)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Antiheart antibody (AHA)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Antiviral antibody (AVA)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Antiviral response to viral infections
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Viral prevalence
Number of subjects: 400

Group type: COMPARATOR
Intervention: Negative AHA
Number of subjects: 400
Study: 30391343

Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Control group (substance-free dormitory floors)
Number of subjects: 1342
Study: 28504921

Group type: EXPERIMENTAL
Intervention: Plasminogen Activator Inhibitor-1 (PAI-1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Homeostatic model assessment of insulin resistance
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum triglycerides
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pericardial fat
Number of subjects: 51
Study: 25553747

Group type: EXPERIMENTAL
Intervention: Family Intervention for Improving Occupational Performance (FI-OP) program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Playroom program
Number of subjects: 37
Study: 23552336

Group type: EXPERIMENTAL
Intervention: Exercise program (12 sessions for 6 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (generic exercise advice leaflet)
Number of subjects: 22
Study: 20978279

Group type: EXPERIMENTAL
Intervention: benazepril
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: benazepril and losartan
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 339
Study: 19446890

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily, p.o.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 21
Study: 17254831

Group type: EXPERIMENTAL
Intervention: Vaccine uptake among students with younger, male, or not literate family heads.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccine uptake among students from households with higher per-capita income.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Residency south of the river or further from a hospital/polyclinic.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger students compared to older students in high- or low-risk areas.
Number of subjects: 0
Study: 15658548

Group type: EXPERIMENTAL
Intervention: Vitrum osteomag (2 tablets daily for 12 months)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1500 mg)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control group (only observation)
Number of subjects: 334
Study: 11293926

Group type: EXPERIMENTAL
Intervention: Orocal D3 (500 mg calcium and 400 IU vitamin D3) taken in two doses at 6-hour intervals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cacit vitamin D3 (1000 mg calcium and 880 IU vitamin D3) taken as a single morning dose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 12
Study: 9527329

Group type: EXPERIMENTAL
Intervention: 4 mm incision
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 6 mm incision
Number of subjects: 197
Study: 8196849

Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF 20 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Naproxen 1000 mg/day
Number of subjects: 61
Study: 2853518

Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.4% tropicamide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: labetalol eye drops
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.25% timolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chemical X
Number of subjects: 16
Study: 28943533

Group type: EXPERIMENTAL
Intervention: ST segment re-elevation after PPCI
Number of subjects: 662
Study: 27457969

Group type: EXPERIMENTAL
Intervention: Food selection training game 'Happy goat says' with inhibition manipulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Food selection training game 'Happy goat says' with impulsivity manipulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Food selection training game 'Happy goat says' with control manipulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group playing Lego blocks
Number of subjects: 20
Study: 24858916

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 22461276

Group type: EXPERIMENTAL
Intervention: Noveon laser treatment for onychomycosis
Number of subjects: 0
Study: 20978719

Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose
Number of subjects: 36

Group type: COMPARATOR
Intervention: Copal varnish
Number of subjects: 36
Study: 18843441

Group type: EXPERIMENTAL
Intervention: Single-hitch throw on suture material
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Addition of an extra throw in 2 x 1 x 1, 2 x 2, and 2 x 2 x 1 knots
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: Four-throw knot configurations
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: 2 x 2 knots
Number of subjects: 2160
Study: 16491148

Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone graft plus 10% collagen (BO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone graft plus 10% collagen with bioresorbable collagen barrier (BO/BG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between BO and BO/BG
Number of subjects: 20
Study: 12960596

Group type: EXPERIMENTAL
Intervention: Lymphatic mapping with labelled colloid and patent blue violet
Number of subjects: 16
Study: 10726910

Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment (16 weeks)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Bezafibrate treatment (8 weeks)
Number of subjects: 342
Study: 9292071

Group type: EXPERIMENTAL
Intervention: Topical all‐trans retinoic acid (RA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tandem application of RA and SLS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS) followed by topical all‐trans retinoic acid (RA)
Number of subjects: 0
Study: 1606395

Group type: EXPERIMENTAL
Intervention: Intratracheal N-acetylcysteine (5% N-acetylcysteine administered every 4 hours for one week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo (administered every 4 hours for one week)
Number of subjects: 10
Study: 3860334

Group type: EXPERIMENTAL
Intervention: Educational intervention (classroom preventive dentistry presentations)
Number of subjects: 854

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 854
Study: 29992600

Group type: EXPERIMENTAL
Intervention: 4-week home-based self-help psychoeducation program
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 27503288

Group type: EXPERIMENTAL
Intervention: rs117026326 on GTF2I
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: rs13079920 on RBMS3
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: rs13072846
Number of subjects: 242
Study: 24183460

Group type: EXPERIMENTAL
Intervention: 6 cycles of FEC100
Number of subjects: 837

Group type: COMPARATOR
Intervention: 4 FEC100 followed by 4 Taxol (4FEC100-4T)
Number of subjects: 837
Study: 23136273

Group type: EXPERIMENTAL
Intervention: AAQ (artesunate amodiaquine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAQ + AMX (artesunate amodiaquine with amoxicillin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAQ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study: 19935071

Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with 1 microg kg(‐1) dexmedetomidine
Number of subjects: 30
Study: 18550508

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: High homocysteine levels
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Homocysteine levels
Number of subjects: 96
Study: 16117995

Group type: EXPERIMENTAL
Intervention: Valsartan treatment
Number of subjects: 603
Study: 12861400

Group type: EXPERIMENTAL
Intervention: Mucosal defect suturing (Group I)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No mucosal defect suturing (Group II)
Number of subjects: 10
Study: 10235025

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with stem cell support (induction with cyclophosphamide and taxol, followed by three high dose cycles of carboplatin, taxol, etoposide, and melphalane)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional chemotherapy (as per AGO-Ovar-5-study)
Number of subjects: 49
Study: 9112171

Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml MMC
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.2 mg/ml MMC
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no MMC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3)
Number of subjects: 29
Study: 1989739

Group type: EXPERIMENTAL
Intervention: Hose method of oxygen supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Face mask oxygen supplementation
Number of subjects: 66
Study: 6348714

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 25 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 31305423

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CPAP therapy)
Number of subjects: 0
Study: 30008787

Group type: EXPERIMENTAL
Intervention: Fermented Laminaria japonica (FST) 1.5 g/day for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 40
Study: 25401715

Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 40 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram (10 to 20 mg/d)
Number of subjects: 0
Study: 22550847

Group type: EXPERIMENTAL
Intervention: Ayurved Siriraj Wattana Recipe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 0
Study: 20191481

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 32
Study: 18022546

Group type: EXPERIMENTAL
Intervention: Therapeutic cancer vaccines (including inactivated tumor cells, heat shock protein vaccines, anti-ganglioside antibodies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies to expand antitumor T lymphocytes and adoptively transfer them to patients
Number of subjects: 0
Study: 15350323

Group type: EXPERIMENTAL
Intervention: Implantation of the ICL
Number of subjects: 294